COVID-19: angiotensin-converting enzyme 2 (ACE2) e... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

Full text
Author(s):
Beyerstedt, Stephany [1] ; Casaro, Expedito Barbosa [1] ; Rangel, Erika Bevilaqua [2, 1]
Total Authors: 3
Affiliation:
[1] Hosp Israelita Albert Einstein, Albert Einstein Res & Educ Inst, 627 Albert Einstein Ave, Bldg A, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Nephrol Div, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES; v. 40, n. 5 JAN 2021.
Web of Science Citations: 6
Abstract

COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. Angiotensin-converting enzyme 2 (ACE2) is not only an enzyme but also a functional receptor on cell surfaces through which SARS-CoV-2 enters the host cells and is highly expressed in the heart, kidneys, and lungs and shed into the plasma. ACE2 is a key regulator of the renin-angiotensin-aldosterone system (RAAS). SARS-CoV-2 causes ACE/ACE2 balance disruption and RAAS activation, which leads ultimately to COVID-19 progression, especially in patients with comorbidities, such as hypertension, diabetes mellitus, and cardiovascular disease. Therefore, ACE2 expression may have paradoxical effects, aiding SARS-CoV-2 pathogenicity, yet conversely limiting viral infection. This article reviews the existing literature and knowledge of ACE2 in COVID-19 setting and focuses on its pathophysiologic involvement in disease progression, clinical outcomes, and therapeutic potential. (AU)

FAPESP's process: 17/23195-2 - Mesenchymal stem cell therapy for halting the progression of acute and chronic kidney injury and in vivo modulate kidney-derived c-Kit stem cells
Grantee:Érika Bevilaqua Rangel
Support Opportunities: Regular Research Grants